Table 2.
Demographical and clinical features at non-Hodgkin lymphoma diagnosis
| Variables | Categories | n (%) |
|---|---|---|
| Total | 215 | |
| Gender | Male | 172 (80.0) |
| Age (years) | <35 | 31 (14.4) |
| 35-49 | 136 (63.3) | |
| ≥50 | 48 (22.3) | |
| Mean (SD) | 43.2 (9.0) | |
| Period of Diagnosis | 1998-2002 | 71 (33.0) |
| 2003-2007 | 88 (40.9) | |
| 2008-2012 | 56 (26.1) | |
| IDU | Yes | 96 (42.8) |
| Migrants | Yes | 28 (8.7) |
| Previous AIDS defining event | Yes | 81 (37.7) |
| HBV or/and HCV co-infection | Yes | 111 (51.6) |
| cART | Yes | 172 (80.0) |
| CD4 cell count, cell/mm3 | <200 | 104 (54.2) |
| ≥200 | 88 (45.8) | |
| Mean (SD) | 275.9 (235.3) | |
| CD4/CD8 Ratio | <1 | 158 (89.3) |
| ≥1 | 19 (10.7) | |
| Mean (SD) | 0.46 (0.50) | |
| HIV-RNA, copies/mL | Undetectable | 49 (26.1) |
| Positive | 139 (73.9) | |
| Mean (SD)* | 113208.8 ( 310601.3) | |
| Status at the end of the follow-up | Alive | 117 (54.4) |
| Dead | 98 (45.6) |
Abbreviations: SD Standard Deviation, IDU Intravenous Drug Use, HBV Hepatitis B Virus, HCV Hepatitis C Virus, cART combined Antiretroviral Therapy, *In subjects with positive HIV-RNA.